Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
#gLP1 #Obesity #MetabolicDisease #Biotech #ClinicalTrials #WeightLoss Image: images.axios.com To view or add a comment, sign in 2 - -1 , Very impressive data from phase 2 trial in patients with overweight/obesity treated by small non-peptide GLP-1 RA aleniglipron ACCESS II is a randomized, double-blind, placebo-controlled, clinical study of aleniglipron that enrolled 85 adult participants living with obesity or overweight (defined as a BMI of greater than 25 kg/m2) with at least one weight-related comorbidity
The addition of glucagon receptor agonism makes its molecular behavior fundamentally different from dual-agonists currently being studied
PubMed Link Standard oral Glutathione has very poor bioavailability (approximately 10-15%)
Factors that support a diverse, healthy microbiomeincluding consuming fermented foods (yoghurt, kefir, sauerkraut), minimising unnecessary antibiotic use, and eating a varied, fibre-rich dietmay indirectly support metabolic health
It could also help the company stay ahead of its rivals in the diabetes and obesity category, notably Eli Lilly, which has also faced supply issues with diabetes therapy Mounjaro and obesity drug Zepbound, based on dual GLP-1/GIP agonist tirzepatide
US$ 20.75
US$ 22.33
US$ 28.45
US$ 22.91
